ELEV Elevation Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ELEV

Price (delayed)

$3.7

Market cap

$202.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.98

Enterprise value

$142.34M

Highlights
ELEV's equity has soared by 125% year-on-year and by 38% since the previous quarter
Elevation Oncology's quick ratio has surged by 122% QoQ
The debt has grown by 4.1% YoY and by 2.2% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: TMUS APPS T

Key stats

What are the main financial stats of ELEV
Market
Shares outstanding
54.64M
Market cap
$202.16M
Enterprise value
$142.34M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.37
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$39.43M
EBITDA
-$39.39M
Free cash flow
-$48.92M
Per share
EPS
-$0.98
Free cash flow per share
-$1.03
Book value per share
$1.56
Revenue per share
$0
TBVPS
$2.3
Balance sheet
Total assets
$108.96M
Total liabilities
$33.14M
Debt
$30.81M
Equity
$75.82M
Working capital
$105.55M
Liquidity
Debt to equity
0.41
Current ratio
46.22
Quick ratio
44.58
Net debt/EBITDA
1.52
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-38.5%
Return on equity
-59.3%
Return on invested capital
-76.8%
Return on capital employed
-37%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ELEV stock price

How has the Elevation Oncology stock price performed over time
Intraday
-3.14%
1 week
2.21%
1 month
-28.43%
1 year
6.02%
YTD
589.01%
QTD
-27.88%

Financial performance

How have Elevation Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$38.57M
Net income
-$39.35M
Gross margin
N/A
Net margin
N/A
ELEV's net income has soared by 59% YoY and by 14% QoQ
Elevation Oncology's operating income has surged by 59% YoY and by 15% QoQ

Growth

What is Elevation Oncology's growth rate over time

Valuation

What is Elevation Oncology stock price valuation
P/E
N/A
P/B
2.37
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 76% year-on-year and by 27% since the previous quarter
ELEV's equity has soared by 125% year-on-year and by 38% since the previous quarter
ELEV's P/B is 98% above its last 4 quarters average of 1.2

Efficiency

How efficient is Elevation Oncology business performance
The return on equity has surged by 60% year-on-year and by 28% since the previous quarter
Elevation Oncology's ROA has soared by 59% YoY and by 21% from the previous quarter
ELEV's ROIC has soared by 55% YoY and by 18% QoQ

Dividends

What is ELEV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELEV.

Financial health

How did Elevation Oncology financials performed over time
Elevation Oncology's quick ratio has surged by 122% QoQ
Elevation Oncology's current ratio has soared by 118% from the previous quarter
The debt is 59% less than the equity
ELEV's equity has soared by 125% year-on-year and by 38% since the previous quarter
The debt to equity has plunged by 53% YoY and by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.